Ventas (VTR) Q1 2026 Earnings Preview: FFO Growth & Valuation

Font: Financial Modeling Prep  • Apr 27, 2026

Ventas (NYSE:VTR) Q1 2026 Earnings Preview: FFO Growth Amidst Valuation Concerns

Ventas (NYSE:VTR) anticipates Q1 2026 revenue between $1.58 billion and $1.59 billion, with an expected earnings per share (EPS) of $0.12.
The healthcare REIT projects a strong 8.3% increase in normalized Funds From Operations (FFO) to $0.91 per share, driven by high occupancy in its senior housing and medical portfolios.
Despite positive FFO outlook, Ventas faces challenges including weakness in leased properties, higher interest expenses, a Debt-to-Equity ratio of 1.06, and potential overvaluation, with recent insider selling.

Ventas (NYSE:VTR) is a real estate investment trust, or REIT. A REIT is a company that owns and often operates income-producing real estate. Ventas focuses on properties in the healthcare industry, including senior housing communities, medical office buildings, and research centers.

Ventas is scheduled to release its first-quarter 2026 earnings on April 27, 2026. For the quarter, Wall Street analysts expect revenue to be between $1.58 billion and $1.59 billion. The consensus earnings per share (EPS) estimate, which measures a company's profit per share of stock, is $0.12.

For REITs, investors also watch a metric called Funds From Operations (FFO). As highlighted by Zacks Investment Research, analysts expect Ventas's normalized FFO to be $0.91 per share, an 8.3% increase from last year. This positive outlook is driven by high occupancy and demand in its senior housing and medical portfolios.

However, there are potential challenges. These include weakness in some of Ventas's leased properties and the impact of higher interest expenses on its finances. The company's Debt-to-Equity ratio, which compares debt to shareholder equity, is 1.06, indicating it uses a significant amount of debt.

On April 21, 2026, Ventas's stock price fell 3.0% to $82.11. An analysis from gurufocus suggests the stock may be overvalued, trading above its estimated value of $64.58. In the last three months, company insiders have also sold $4.7 million worth of shares with no reported purchases.